Becton Dickinson vs. Beckman Coulter: Fluorescent Dye Patent Dispute Ends in Mutual Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Becton, Dickinson and Company v. Beckman Coulter, Inc. |
| Case Number | 3:21-cv-01173 (S.D. Cal.) |
| Court | U.S. District Court for the Southern District of California |
| Duration | June 2021 – July 2024 3 years |
| Outcome | Mutual Dismissal With Prejudice |
| Legal Reps | Plaintiffs: Barbara A. Fiacco (Foley Hoag LLP) Defendant: David M. Krinsky (Williams & Connolly LLP) |
| Patents at Issue | |
| Accused Products | Beckman Coulter’s SuperNova Dyes and corresponding dye-antibody conjugates |
Case Overview
The Parties
⚖️ Plaintiffs
A global medical technology leader with extensive IP holdings in diagnostics and life sciences instrumentation. Co-plaintiffs Sirigen, Inc. and Sirigen II Limited are BD subsidiaries specializing in conjugated polymer dye technologies.
🛡️ Defendant
A Danaher Corporation subsidiary and major competitor in flow cytometry instrumentation and reagent systems. Its SuperNova Dye line directly competes with BD’s Brilliant dye products.
Patents at Issue
This case involved 13 U.S. patents covering conjugated polymer fluorescent dye technologies, foundational to modern multi-parameter flow cytometry panels. These patents collectively protect the synthesis, composition, and application of **conjugated polymer-based fluorescent dyes** and **dye-antibody conjugates**.
- • US10641775B2 | US9139869B2 | US8362193B2
- • US10302648B2 | US10288620B2 | US8455613B2
- • US9547008B2 | US10955417B2 | US8575303B2
- • US10458989B2 | US10962546B2 | US10094838B2
- • US10365285B2
Developing a new fluorescent dye or reagent?
Check if your product might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
On July 12, 2024, the parties filed a **Joint Motion and Stipulation of Dismissal** pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii). The court granted the motion, ordering plaintiffs’ claims and defendant’s counterclaims dismissed **with prejudice**, with each party bearing its own costs. No damages award was disclosed, and no injunctive relief was ordered, strongly suggesting a **confidential settlement agreement**.
Key Legal Issues
The litigation centered on **patent infringement** across 13 conjugated polymer dye patents. Beckman Coulter’s litigation posture likely included invalidity counterclaims, potentially challenging patents on grounds of prior art or enablement. The breadth of the patent portfolio asserted created comprehensive infringement exposure. The dismissal with prejudice of Beckman Coulter’s counterclaims precludes re-litigation of those specific challenges, a meaningful concession that may have formed part of settlement negotiations.
While the case produced no published claim construction ruling or validity determination, its significance lies in the strategic use of a broad patent portfolio for litigation leverage and the ultimate resolution through a mutual Rule 41 dismissal, which permanently extinguishes all claims and counterclaims.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the fluorescent dye and reagent space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 13 asserted patents in this technology space
- See which companies are most active in fluorescent dyes
- Understand conjugated polymer dye claim patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Conjugated polymer dye compositions
13 Asserted Patents
In fluorescent dye space
Strategic Resolution
Via confidential settlement
✅ Key Takeaways
Thirteen-patent portfolio assertions create compounding invalidity burdens for defendants and substantial settlement leverage for plaintiffs.
Search related case law →Dismissal with prejudice of counterclaims extinguishes invalidity challenges permanently — a critical negotiating point in settlement discussions.
Explore precedents →Rule 41(a)(1)(A)(ii) joint dismissals in complex patent cases frequently signal confidential commercial resolutions.
Understand procedural dynamics →Frequently Asked Questions
The case involved 13 U.S. patents (including US10641775B2, US9139869B2, US8362193B2, and ten additional patents) covering conjugated polymer fluorescent dye technologies assigned to Becton Dickinson and its Sirigen subsidiaries.
Both parties filed a joint stipulation of dismissal under FRCP Rule 41(a)(1)(A)(ii) on July 12, 2024, indicating a mutually agreed resolution. Dismissal with prejudice permanently bars re-litigation of the same claims.
The unresolved judicial record leaves BD’s 13-patent portfolio legally intact and untested by verdict, maintaining ongoing IP risk for competitors developing conjugated polymer dye technologies in the flow cytometry reagent market.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Lookup – Case No. 3:21-cv-01173
- USPTO Patent Full-Text Database
- Southern District of California Court Records
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.